Abstract
Because of reports of occasional objective responses in renal cell carcinoma with chlorozotocin in phase I studies and reported activity of CCNU in this disease, the present phase II study was initiated. Twenty-one patients with histologically confirmed unresectable renal cell carcinoma were entered in this study between June 1977 and February 1978. No significant tumor regression occurred in the 21 chlorozotocin-treated patients. The treatment group included patients with a good PS who experienced myelosuppression secondary to chlorozotocin. In addition, 14 of 21 (67%) of the patients had received no prior hormonal or myelosuppressive chemotherapy. Because no PRs were achieved in this number of patients, it can be concluded that chlorozotocin is likely to have a true major response rate of <15%. The drug would appear to have little therapeutic value in this schedule as a single agent in patients with advanced renal cell carcinoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1007-1008 |
| Number of pages | 2 |
| Journal | Cancer Treatment Reports |
| Volume | 63 |
| Issue number | 6 |
| State | Published - 1979 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research
